Patents by Inventor Hachiro Sugimoto

Hachiro Sugimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220031787
    Abstract: The problems to be solved by the present invention are to provide a novel agent for preventing and/or treating a neurodegenerative disease, and a pharmaceutical composition comprising the agent for preventing and/or treating a neurodegenerative disease. The problems are solved by providing an agent for preventing and/or treating a neurodegenerative disease, the agent comprising as an active ingredient an extract of Momordica charantia var. pavel, and preferably the agent is for use in treatment or prevention of a disease selected from Alzheimer's disease, Parkinson's disease, Down syndrome, tauopathy (for example, argyrophilic grain dementia, senile dementia of neurofibrillary tangle type, progressive supranuclear palsy, degeneration of cerebral cortex or Pick disease), and dementia with lewy bodies.
    Type: Application
    Filed: November 12, 2019
    Publication date: February 3, 2022
    Applicants: GREEN TECH CO., LTD., McB.,Co.
    Inventors: Hachiro SUGIMOTO, Koki NAGASHIMA, Michiaki OKUDA, Yuki FUJITA
  • Publication number: 20210393551
    Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.
    Type: Application
    Filed: September 1, 2021
    Publication date: December 23, 2021
    Inventors: Akihiko TAKASHIMA, Yoshiyuki SOEDA, Hiroyuki OSADA, Yasuo IHARA, Tomohiro MIYASAKA, Hachiro SUGIMOTO
  • Publication number: 20180161288
    Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: Akihiko TAKASHIMA, Yoshiyuki SOEDA, Hiroyuki OSADA, Yasuo IHARA, Tomohiro MIYASAKA, Hachiro SUGIMOTO
  • Patent number: 9907799
    Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: March 6, 2018
    Assignees: THE DOSHISHA, National Center for Geriatrics and Gerontology
    Inventors: Tomohiro Miyasaka, Hachiro Sugimoto, Rie Tokizane, Yuki Shinzaki, Yohei Oe, Tetsuo Ota, Akihiko Takashima, Yoshiyuki Soeda, Yasuo Ihara, Yoshikazu Inoue
  • Patent number: 9724333
    Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: August 8, 2017
    Assignee: GREEN TECH CO., LTD.
    Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
  • Publication number: 20160228412
    Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 11, 2016
    Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
  • Patent number: 9399635
    Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: July 26, 2016
    Assignee: GREEN TECH CO., LTD.
    Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
  • Patent number: 9321752
    Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: April 26, 2016
    Assignee: GREEN TECH CO., LTD.
    Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
  • Publication number: 20160030437
    Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).
    Type: Application
    Filed: April 2, 2014
    Publication date: February 4, 2016
    Inventors: Tomohiro Miyasaka, Hachiro Sugimoto, Rie Tokizane, Yuki Shinzaki, Yohei Oe, Tetsuo Ota, Akihiko Takashima, Yoshiyuki Soeda, Yasuo Ihara, Yoshikazu Inoue
  • Publication number: 20150252029
    Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.
    Type: Application
    Filed: September 17, 2013
    Publication date: September 10, 2015
    Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
  • Patent number: 8987486
    Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: March 24, 2015
    Assignees: Nagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co., Ltd.
    Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto
  • Patent number: 8962674
    Abstract: The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on A? aggregation, a degradative effect on A? aggregates, an inhibitory effect on ?-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: February 24, 2015
    Assignees: Tokyo Institute of Technology, Kyoto University
    Inventors: Takashi Takahashi, Ichiro Hijikuro, Hachiro Sugimoto, Takeshi Kihara, Yoshiari Shimmyo, Tetsuhiro Niidome
  • Publication number: 20140249180
    Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.
    Type: Application
    Filed: October 3, 2012
    Publication date: September 4, 2014
    Applicants: National Center for Geriatrics and Gerontology, THE DOSHISHA
    Inventors: Akihiko Takashima, Yoshiyuki Soeda, Hiroyuki Nagata, Yasuo Ihara, Tomohiro Miyasaka, Hachiro Sugimoto
  • Patent number: 8686024
    Abstract: The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R4 each independently represents a hydrogen atom or an alkyl group; and R5 represents a hydrogen atom or an alkyl group.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: April 1, 2014
    Assignees: Kyoto University, Tokyo Institute of Technology
    Inventors: Hachiro Sugimoto, Jun Takahashi, Takashi Takahashi, Ichiro Hijikuro
  • Publication number: 20140088029
    Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.
    Type: Application
    Filed: April 11, 2012
    Publication date: March 27, 2014
    Applicant: PHARMA EIGHT CO., LTD.
    Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
  • Patent number: 8552220
    Abstract: To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH?CH.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: October 8, 2013
    Assignees: Tokyo Institute of Technology, Kyoto University
    Inventors: Hachiro Sugimoto, Takashi Takahashi, Ichiro Hijikuro, Michiaki Okuda
  • Publication number: 20130225837
    Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.
    Type: Application
    Filed: November 1, 2011
    Publication date: August 29, 2013
    Applicants: Nippon Zoki Pharmaceutical Co., Ltd., Nagoya Industrial Science Research Institute
    Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto
  • Publication number: 20110294850
    Abstract: The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R4 each independently represents a hydrogen atom or an alkyl group; and R5 represents a hydrogen atom or an alkyl group.
    Type: Application
    Filed: February 3, 2010
    Publication date: December 1, 2011
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, KYOTO UNIVERSITY
    Inventors: Hachiro Sugimoto, Jun Takahashi, Takashi Takahashi, Ichiro Hijikuro
  • Publication number: 20110082295
    Abstract: To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH?CH.
    Type: Application
    Filed: May 27, 2009
    Publication date: April 7, 2011
    Applicants: Tokyo Institute of Technology, Kyoto University
    Inventors: Hachiro Sugimoto, Takashi Takahashi, Ichiro Hijikuro, Michiaki Okuda
  • Publication number: 20100048901
    Abstract: The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on A? aggregation, a degradative effect on A? aggregates, an inhibitory effect on ?-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.
    Type: Application
    Filed: November 30, 2007
    Publication date: February 25, 2010
    Applicants: TOKYO INSTITUTE OF TECHNOLOGY, Kyoto University
    Inventors: Takashi Takahashi, Ichiro Hijikuro, Hachiro Sugimoto, Takeshi Kihara, Yoshiari Shimmyo, Tetsuhiro Niidome